{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","spread":"8.59","value":"93.9"}]}],"title":"Tumor"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"9.04","value":"63.2"}]}],"title":"Rectum"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"12.05","value":"58.63"}]}],"title":"Sigmoid"}],"denoms":[{"counts":[{"groupId":"OG000","value":"84"}],"units":"Participants"}],"description":"Doses given to the tumor, rectum, and sigmoid obtained after AMIGO-guided placement.","dispersionType":"Standard Deviation","groups":[{"description":"Image-guided brachytherapy\n\nImage-guided brachytherapy: MRI-guided application of brachytherapy\n\n3'-Deoxy-3'-18f-Fluorothymidine: Assessing tumor proliferation in Gynecologic cancer","id":"OG000","title":"Image-Guided Brachytherapy"}],"paramType":"MEAN","reportingStatus":"POSTED","timeFrame":"Measured while on treatment, up to 2 months.","title":"Mean Doses Given","type":"PRIMARY","unitOfMeasure":"Gy"}